12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Synavive: Development discontinued

Zalicus discontinued development of Synavive after the double-blind, international Phase IIb SYNERGY trial in 259 patients with moderate to severe RA showed that the compound missed the secondary endpoint of reducing DAS28-CRP scores from baseline to week 12 vs. 2.7 mg prednisolone, the active glucocorticoid component of Synavive (0.9 vs. 1.125 points). Synavive did meet the primary endpoint of...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >